Blog
RSS FeedPosted by Michael Wonder on 12 Mar 2019
NICE u-turn backs use of Darzalex combo for myeloma relapse
12 March 2019 - Myeloma patients in England are set to gain NHS access to a new second-line treatment combination ...
Posted by Michael Wonder on 06 Mar 2019
NICE evidence request for Blincyto for acute lymphoblastic leukaemia
6 March 2019 - NICE has requested further evidence on Amgen’s Blincyto (blinatumomab) for the treatment of adults with acute ...
Posted by Michael Wonder on 25 Feb 2019
Family fight for cancer treatment in USA because drugs not available in UK
25 February 2019 - A mother of four from Downham Market in west Norfolk says she won't live to 50 ...
Posted by Michael Wonder on 21 Feb 2019
Linking cancer drug prices to treatment success could speed up approvals. But what do patients consider success?
21 February 2019 - The NHS spends more than £2 billion on cancer drugs each year in the UK. And ...
Posted by Michael Wonder on 20 Feb 2019
NICE terminates appraisal of combination regimen for patients with advanced platinum-sensitive ovarian cancer
20 February 2019 - The treatment regimen is bevacizumab with carboplatin and gemcitabine hydrochloride and paclitaxel. ...
Posted by Michael Wonder on 16 Feb 2019
Alunbrig recommended by NICE for non-small-cell lung cancer
15 February 2019 - NICE has recommended the use of Alunbrig (brigatinib) for treating ALK-positive advanced non-small-cell lung cancer after ...
Posted by Michael Wonder on 15 Feb 2019
NICE draft guidance recommends pertuzumab for new breast cancer indication after improved price offer from company
15 February 2019 - NICE has published final draft guidance recommending pertuzumab (Perjeta, Roche) for treating early HER2-positive breast cancer in ...
Posted by Michael Wonder on 10 Feb 2019
Patient involvement in reflective multi-criteria decision analysis to assist decision making in oncology
7 February 2019 - Patient involvement in drug evaluation decision making is increasing. ...
Posted by Michael Wonder on 08 Feb 2019
What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries.
7 February 2019 - Decisions on the reimbursement of the same cancer drugs are different across European countries, but empirical work ...
Posted by Michael Wonder on 04 Feb 2019
Mother of four is denied cancer drug that could save her life
2 February 2019 - A British nurse with four children is being denied potentially life-saving cancer treatment that was approved ...
Posted by Michael Wonder on 01 Feb 2019
NICE recommends another revolutionary CAR T-cell therapy for adults with lymphoma
1 February 2019 - Adults with relapsed or refractory diffuse large B-cell lymphoma will be able to access another revolutionary chimeric ...
Posted by Michael Wonder on 18 Jan 2019
NICE OK for Bravtovi skin cancer drug
18 January 2019 - NICE has recommended Pierre Fabre’s Bravtovi (encorafenib) and Mektovi (binimetinib) combination as an option for some ...
Posted by Michael Wonder on 18 Jan 2019
Thousands of adults with chronic lymphocytic leukaemia to benefit from new treatment option
18 January 2019 - Thousands of people will benefit as NICE recommends venetoclax with rituximab for adults with relapsed or refractory ...
Posted by Michael Wonder on 17 Jan 2019
NICE approval for Verzenios in metastatic breast cancer
17 January 2019 - NICE has recommended Eli Lilly’s Verzenios (abemaciclib) in combination with an aromatase inhibitor as treatment option ...
Posted by Michael Wonder on 10 Jan 2019
NICE publishes final guidance on another use of Keytruda for patients with NSCLC
10 January 2019 - This time it is for patients with untreated, metastatic non-squamous non-small cell lung cancer. ...